# Title:

COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study

# Orientation Statement:

This paper studies the use of convalescent blood plasma (CBP) in the treatment of moderate and sever cases of COVID-19.

# Claim:

Among those with moderate COVID-19 disease, time to clinical improvement was 7 days in the CBP group, versus 8 days in the control group. The data show that administration of CBP is a safe treatment option for patients with COVID-19 disease with a favorable outcome in the rate of, and time to, clinical improvement.

# Changes:

* Add content
* Masking
* Polarity shift
* Change Numbers